Skyclarys Pregnancy Warnings
Animal studies have revealed evidence of increased stillbirths and impaired neurobehavioral function in offspring. At the highest dose tested, it reduced body weight, delayed sexual maturity in males, increased postnatal mortality, and impaired reproductive performance in offspring. There are no controlled data in human pregnancy.
Safety has not been established during pregnancy.
US FDA pregnancy category: Not assigned
Risk summary: No data available on the use of this drug in pregnant women to inform a drug-related risk.
Comments: Women of childbearing potential using hormonal contraceptives should be advised to use alternative methods during therapy and for 28 days after discontinuation.
See references